

# Xbrane Biopharma AB ("Xbrane" or the "Company") announces changes to the number of shares and votes in the Company.

**The number of shares and votes in Xbrane have changed following the issue of 79,252 shares during October through exercise of warrants under LTIP 2020, adopted at the annual general meeting 2020.**

As of October 31, 2023, the total number of shares and votes in the Company amounts to 29,810,364. The Company's registered share capital amounts to about SEK 6,683,068.

## Contacts

---

Martin Åmark, CEO  
M: +46 76 309 37 77  
E: [martin.amark@xbrane.com](mailto:martin.amark@xbrane.com)

Anette Lindqvist, CFO/IR  
M: +46 76 325 60 90  
E: [anette.lindqvist@xbrane.com](mailto:anette.lindqvist@xbrane.com)

## About Us

---

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 53 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during the first quarter 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit [www.xbrane.com](http://www.xbrane.com)

*This information is information that Xbrane Biopharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-10-31 13:00 CET.*

## Attachments

---

[Xbrane Biopharma AB \("Xbrane" or the "Company"\) announces changes to the number of shares and votes in the Company.](#)